- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04626973
Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial
June 9, 2021 updated by: Yonsei University
Although the clinical efficacy of LDL-cholesterol lowering therapy has been proven with strong evidences and emphasized, there are also growing concerns that intensive lipid-lowering therapy would be related to increased risk of adverse effects.
In addition, statin potency from recent guidelines was set from the studies composed of mainly Caucasian population, although there is an inconsistency of statin effect according to ethnicity.
Asian population showed more profound LDL reduction not only from high potent statin but also from moderate to low potent statin.
Conventional strategies for lowering LDL-cholesterol focused on statins, therefore doubling of previously described dose of statin would be common way in patients with inadequate LDL-cholesterol levels.
Adding ezetimibe will be an alternative strategy not only to lower LDL-cholesterol level and also to reduce the need of dosage of high-intensity statin to achieve sufficient LDL-cholesterol lowering effect.
However, studies regarding the effect of intensive-targeting of lipid-lowering therapy and therapy regimens are lacking.
Thus, on these basis, we sought to evaluate whether intensive-targeting of lipid-lowering therapy will have more prominent beneficial effect compared to conventional-targeting in patients with documented ASCVD with either an ezetimibe/statin combination therapy or a statin monotherapy.
Study Overview
Status
Recruiting
Conditions
Detailed Description
All eligible patients who have documented ASCVD will be enrolled according to inclusion/exclusion criteria after voluntary agreement with informed consent.
At the time of enrollment, we will stratify all patients according to LDL-cholesterol <100mg/dL, DM, and acute coronary syndrome, and randomly assign them in two groups according to LDL-cholesterol targeting level with a 1:1 ratio: "Intensive-targeting group" vs. "Conventional-targeting group".
In addition, patients in each group will be randomly assigned to receive two lipid-lowering therapy regimen with a 1:1 ratio: "Ezetimibe/Statin combination therapy" vs. "Statin monotherapy".
Patients allocated to each treatment group will receive lipid-lowering therapy with following protocols.
Study Type
Interventional
Enrollment (Anticipated)
3048
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Byeong-Keuk Kim, MD, PhD
- Phone Number: 82-2-2228-8465
- Email: KIMBK@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
-
Contact:
- Byeong-Keuk Kim, MD, PhD
- Phone Number: 82-2-2228-8465
- Email: KIMBK@yuhs.ac
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 19-80 years
Documented atherosclerotic cardiovascular disease (ASCVD)
- Previous acute coronary syndrome (myocardial infarction [MI] or unstable angina),
- Or stable angina with imaging or functional studies
- Or coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG], and other arterial revascularization procedures)
- Or stroke and transient ischemic attack (TIA)
- Or peripheral artery disease
Exclusion Criteria:
- LDL-cholesterol level less than 70 mg/dL without statin therapyAllergy or hypersensitive to ezetimibe or statin
- Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range
- Allergy or hypersensitivity to any statin or ezetimibe
- Solid organ transplantation recipient
- Pregnant women, women with potential childbearing, or lactating women
- Life expectancy less than 3 years
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
- Inability to understand or read the informed content
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intensive-targeting group
|
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
|
ACTIVE_COMPARATOR: Conventional-targeting group
|
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical outcomes by different lipid-lowering therapy
Time Frame: Within 3 years after the enrollment
|
Composite of cardiovascular death, non-fatal MI, non-fatal stroke, any revascularization, and hospitalization for angina
|
Within 3 years after the enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Each component of primary endpoint within 3 years
Time Frame: Within 3 years after the enrollment
|
|
Within 3 years after the enrollment
|
Various composite outcomes within 3 years
Time Frame: Within 3 years after the enrollment
|
|
Within 3 years after the enrollment
|
Proportion of subjects achieving target LDL-cholesterol level
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of cross-over into the non-allocated therapy regimen in order to achieve target LDL-cholesterol level
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Proportions of subjects requiring proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to achieve target LDL-cholesterol level
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Difference in rate of primary outcome according to sex
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Difference in rate of primary outcome according to body mass index
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of New-onset diabetes mellitus
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of worsening of glycemic control or homeostatic model assessment (HOMA)-index
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Occurrence of statin-associated muscle symptoms (SAMS) requiring change of therapy regimen or dosage
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Occurence of elevation of muscle enzymes (CPK > 4 x UNL)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Occurence of elevation of hepatic enzymes (AST, ALT, or both ≥ 3 x UNL)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Occurence of elevation of serum creatinine level (>50% from baseline)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Change of proteinuria
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of cancer diagnosis
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of operation due to cataract
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Byeong-Keuk Kim, MD, PhD, Severance Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 15, 2021
Primary Completion (ANTICIPATED)
September 1, 2025
Study Completion (ANTICIPATED)
September 1, 2025
Study Registration Dates
First Submitted
October 20, 2020
First Submitted That Met QC Criteria
November 8, 2020
First Posted (ACTUAL)
November 13, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 11, 2021
Last Update Submitted That Met QC Criteria
June 9, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Cardiovascular Diseases
- Atherosclerosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Ezetimibe
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
Other Study ID Numbers
- 4-2020-0903
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerotic Cardiovascular Disease
-
Novartis PharmaceuticalsNot yet recruitingElevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
-
Advanced Education & Research CenterUniversity of Karachi; Pakistan Cardiac Society (Heart House)RecruitingAtherosclerotic Cardiovascular Diseases (ASCVD)Pakistan
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein CholesterolUnited Kingdom
-
Eli Lilly and CompanyRecruitingElevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)Taiwan, United States, Spain, Argentina, China, Italy, Australia, France, Canada, Japan, Belgium, Denmark, Germany, Hungary, Israel, Austria, Korea, Republic of, Brazil, Mexico, Netherlands, Romania, United Kingdom, Greece, Czechia, India, Slovak... and more
-
AmgenRecruitingMajor Cardiovascular Event | Established Atherosclerotic Cardiovascular DiseaseChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Pauls Stradins Clinical University HospitalActive, not recruitingAtherosclerotic Cardiovascular DiseaseLatvia
-
Pieter MuntendamIcahn School of Medicine at Mount Sinai; AstraZenecaEnrolling by invitationHeart Diseases | Stroke | Plaque, Atherosclerotic | Cardiovascular Risk Factor | Atherosclerotic DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Blood Pressure | Subclinical Atherosclerotic Cardiovascular DiseaseUnited States
-
Kahramanmaras Sutcu Imam UniversityCompletedCoronary Artery Disease | Progression of Atherosclerotic PlaqueTurkey
Clinical Trials on Ezetimibe/Statin Combination therapy
-
AkrikhinRussian National Atherosclerosis SocietyCompletedCardiovascular Diseases | Lipid Metabolism DisordersRussian Federation
-
Yonsei UniversityRecruitingCoronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES ImplantationKorea, Republic of
-
Seoul National University Bundang HospitalYuhan CorporationCompletedCardiovascular DiseasesKorea, Republic of
-
Samsung Medical CenterNot yet recruitingMetabolic Syndrome | Dyslipidemias | Coronary Artery Calcification
-
University of Roma La SapienzaUnknown
-
NewAmsterdam PharmaRecruitingDyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | High Cholesterol | ASCVDUnited States
-
Brasilia Heart Study GroupCompletedMyocardial InfarctionBrazil
-
Daewoong Pharmaceutical Co. LTD.RecruitingDyslipidemiasKorea, Republic of
-
Organon and CoCompleted